분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-06-15 12:33:12 , Hit : 2223
 Biotech industry worries over Supreme Court DNA ruling

By Paul Handley, AFP

Posted:   06/13/2013 06:05:03 PM MDT
June 14, 2013

WASHINGTON — The US Supreme Court's rejection Thursday of natural DNA patent protection could hurt biotech companies, but specialists said it left enough safeguards for the industry to keep innovating.

The court ruled that Myriad Genetics, which sells expensive tests for the genetic markers for cancer, could not claim patents on the DNA it identified in the 1990s to develop the tests.

Critics said the ruling would inhibit other companies and their financial backers, like venture capitalists, from investing in more genetic sequencing research because they could not patent their discoveries.

"The Supreme Court's decision today represents a troubling departure from decades of judicial and Patent and Trademark Office precedent," said Jim Greenwood, president of the Biotechnology Industry Organization.

Companies "have long relied on patents on preparations of DNA molecules and other biological chemicals in order to bring innovative, socially beneficial products to the marketplace," he said, calling the United States "now the only developed country to take such a restrictive view of patent eligibility."

"This is a real disappointment for the advancement of medical innovation," said Kelly Slone, vice president of the National Venture Capital Association.

"Venture capitalists needs certainty, and that certainty is what patents provide."

But analysts said the ruling was narrow enough to avoid stifling genetic sequencing research by pharmaceutical firms, agrotechnology businesses and others.

"The court clearly is struggling as it has been for years with striking the right balance," said Michael Shuster, a partner at San Francisco law practice Fenwick & West, and a specialist in biotechnology and intellectual property.

"I think that they understand that the biotech industry is a bright spot for the economy."

The court's decision "makes the climate a little more difficult" for companies and their financial backers, "but there are still stategies that can be pursued," said Shuster, who wrote a "friend of the court" brief for the case on behalf of the NVCA.

Nevertheless, he called it "a ruling the industry as a whole can live with."

The Supreme Court justices were clearly sensitive to the case's potential impact.

"Patent protection strikes a delicate balance between creating incentives that lead to creation, invention and discovery and impeding the flow of information that might permit, indeed spur, invention," the justices said.



As a result, they stressed, they did not rule on Myriad's processes for using the DNA, and they upheld the company's patents on synthetic DNA, or cDNA.

Myriad said in a statement that the decision would then ensure it could continue with its main business, selling its tests for the rare BRCA1 and BRCA2 genes that can point to the likelihood of cancer.

The ruling was "very narrow in its focus," said Kevin Noonan, a biotechnology patent lawyer at Chicago practice McDonnell Boehnen Hulbert & Berghoff.

"It's probably the best decision that we could have hoped for."

But Noonan and Shuster highlighted one problem raised by the decision.

By ruling against patenting DNA because it is something freely found in nature, the court reopened questions over existing patent protection for molecules isolated from nature -- such as those used to develop antibiotics and other drugs.

"I don't know if those remain patent-eligible," said Shuster.

One immediate impact from the decision, nevertheless, was that Myriad would face new competition from companies that develop their own tests based on the two genes.

By late Thursday, Ambry Genetics announced it was coming to market with its BRAC1 and BRCA2 analysis "at a competitively lower cost and comparable turnaround time" to Myriad's.

"Your genes have been freed," the company said in a banner headline on its website, above a picture of the Supreme Court.








747    "여성 X염색체에 정자생산 관여 유전자 존재"  이성욱 2013/07/23 2220
746   다운증후군 원인 염색체 침묵화 가능성 확인  이성욱 2013/07/22 2255
745   Stem cells reprogrammed using chemicals alone  이성욱 2013/07/20 2082
744   Scientists find way to silence extra chromosome that causes Down syndrome  이성욱 2013/07/20 2212
743   Gene therapy using HIV helps children with fatal diseases, study says  이성욱 2013/07/16 2017
742   Scientists develop ground-breaking new method of 'starving' cancer cells  이성욱 2013/07/15 2340
741   암 전이(metastasis)로 통하는 문을 공략하라  이성욱 2013/07/09 2376
740   줄기세포 이식으로 HIV 감염 완치: 세계 3번째, 4번째의 HIV 완치 환자 등장  이성욱 2013/07/05 2839
739   줄기세포로 사람 '肝씨앗' 만들어 자라게… 日 세계 첫 성공  이성욱 2013/07/04 2193
738   ‘젊은 유전자’로 안티에이징.. 파괴적 혁신 기술이 미용·항노화산업 발달 촉진  이성욱 2013/07/01 3114
737   생물학적 주기 및 대사 유전자의 간섭과 연관되어 있는 프라더-윌리 증후군  이성욱 2013/06/28 3235
736   日, 유도만능줄기세포 임상연구 세계 최초 승인  이성욱 2013/06/27 2256
735   복제연구를 둘러싼 논쟁  이성욱 2013/06/21 2038
734   유전자 특허 불인정 판결의 후폭풍: 멘붕에 빠진 미 BT 업계  이성욱 2013/06/20 2921
  Biotech industry worries over Supreme Court DNA ruling  이성욱 2013/06/15 2223
732   Potential New Target to Thwart Antibiotic Resistance: Viruses in Gut Confer Antibiotic Resistance to Bacteria  이성욱 2013/06/13 2258
731   장내 미생물균총 변화로 당뇨 예측  이성욱 2013/06/07 2491
730   인헨서의 역할과 인헨서 치료법  이성욱 2013/06/07 2345
729   결핵, 탄저병, 세균성 이질 등에 보다 효과적인 새로운 종류의 항생제 개발  이성욱 2013/06/06 2385
728   미탈리포프 이후, 변화의 조짐을 보이는 미국의 줄기세포 연구환경  이성욱 2013/06/06 2432

[이전 10개] [1]..[21][22][23][24][25][26] 27 [28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN